CN Patent

CN101326175B — C-met/hgfr抑制剂的多晶型物

Assigned to Pfizer Products Inc · Expires 2012-07-18 · 14y expired

What this patent protects

本发明涉及(R)-3-[1-(2，6-二氯-3-氟-苯基)-乙氧基]-5-(1-哌啶-4-基-1H-吡唑-4-基)-吡啶-2-基胺的多晶型物，其可用于治疗哺乳动物中的异常细胞生长，诸如癌症。本发明还涉及包括此类盐和多晶型物的组合物，以及使用所述组合物治疗哺乳动物(尤其是人类)中异常细胞生长的方法。

USPTO Abstract

本发明涉及(R)-3-[1-(2，6-二氯-3-氟-苯基)-乙氧基]-5-(1-哌啶-4-基-1H-吡唑-4-基)-吡啶-2-基胺的多晶型物，其可用于治疗哺乳动物中的异常细胞生长，诸如癌症。本发明还涉及包括此类盐和多晶型物的组合物，以及使用所述组合物治疗哺乳动物(尤其是人类)中异常细胞生长的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN101326175B
Jurisdiction
CN
Classification
—
Expires
2012-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.